HALO · ISSUER CIK 1159036
HALOZYME THERAPEUTICS, INC.
Between Aug 1, 2026 and Oct 29, 2026, 5 HALOZYME THERAPEUTICS, INC. insiders reported $0.00 of open-market purchases and $22.1M of sales on SEC Form 4.
↗5 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 6 of 6 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$22.1MInsider selling
−$22.1MNet open-market
Oct 8, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 8, 202619:56 | Oct 8, 2026from Oct 6, 2026 | HALO | PRESIDENT AND CEO, Director | S · Sell10b5-1 | $110.18 | −60,000 | 767,780 | -7% | −$6.6M | ||
| Oct 8, 202619:56 | Oct 8, 2026from Oct 6, 2026 | HALO | PRESIDENT AND CEO, Director | M · Exercise10b5-1 | $18.41 | +60,000 | 787,780 | +8% | $1.1M | ||
| Oct 2, 202616:43 | Oct 1, 2026 | HALO | Director | A · Grant | — | +1,169 | 1,169 | New | — | ||
| Oct 2, 202616:38 | Oct 1, 2026 | HALO | Director | S · Sell10b5-1 | $108.54 | −5,230 | 53,609 | -9% | −$568K | ||
| Sep 17, 202617:19 | Sep 16, 2026 | HALO | Director | S · Sell10b5-1 | $107.74 | −18,996 | 58,839 | -24% | −$2.0M | ||
| Sep 11, 202620:35 | Sep 11, 2026from Sep 9, 2026 | HALO | PRESIDENT AND CEO, Director | S · Sell10b5-1 | $107.28 | −60,000 | 767,780 | -7% | −$6.4M | ||
| Sep 11, 202620:35 | Sep 11, 2026from Sep 9, 2026 | HALO | PRESIDENT AND CEO, Director | M · Exercise10b5-1 | $18.41 | +60,000 | 787,780 | +8% | $1.1M | ||
| Sep 2, 202616:59 | Sep 1, 2026 | HALO | Director | A · Grant | — | +1,161 | 1,161 | New | — | ||
| Aug 19, 202620:01 | Aug 19, 2026from Aug 17, 2026 | HALO | PRESIDENT AND CEO, Director | S · Sell10b5-1 | $104.59 | −60,000 | 767,780 | -7% | −$6.3M | ||
| Aug 19, 202620:01 | Aug 19, 2026from Aug 17, 2026 | HALO | PRESIDENT AND CEO, Director | M · Exercise10b5-1 | $18.41 | +60,000 | 787,780 | +8% | $1.1M | ||
| Aug 11, 202617:43 | Aug 10, 2026 | HALO | Director | S · Sell10b5-1 | $102.80 | −1,626 | 40,418 | -4% | −$167K |